Freenome CEO says development of cancer test in US relies on Illumina to provide next-generation sequencer
Freenome Chief Executive Mike Nolan said his company must work with Illumina to develop its test to identify early-stage colorectal cancer, underscoring a key point in the US Federal Trade Commission's...To view the full article, register now.
Already a subscriber? Click here to view full article